Imunoterapie u pacientů s karcinomem plic na MOÚ: účinnost, bezpečnost a náklady

Warning

This publication doesn't include Faculty of Education. It includes Faculty of Medicine. Official publication website can be found on muni.cz.

Title in English	Immunotherapy in patients with lung cancer at the Masaryk Memorial Cancer Institute: efficacy, safety and costs
Authors	BÁRTOVÁ Adéla ŘÍHOVÁ Barbora
Year of publication	2023
Type	Conference abstract
MU Faculty or unit	Faculty of Medicine
Citation
Description	The aim of the analysis was to perform a comprehensive evaluation of the efficacy and cost of checkpoint inhibitors (pembrolizumab, nivolumab, durvalumab, atezolizumab and nivolumab in combination with ipilimumab) in patients with metastatic or locally advanced non-small cell lung cancer (NSCLC) based on real clinical data. The analysis also includes a review of the incidence of immune-mediated adverse events in these patients.
Related projects:	CZECRIN - Czech National Node to the European Clinical Research Infrastructure Network Preclinical and clinical research of the Department of Pharmacology in the field of biotransformation of drugs, behavioural neuropsychopharmacology and personalized pharmacotherapy in oncology